Monitor FDA acceptance of the BLA (expected within 60 days) and the priority review decision. The upcoming four-year data presentation before end of Q3 2026 could further de-risk the regulatory path. Any FDA rejection or delay would be a significant negative catalyst.
Drug in focus
QURE drug pipeline →AMT-130
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 1/2 (pivotal for accelerated approval)
- Time to market
- BLA submission planned for Q3 2026; FDA accelerated approval decision likely 6-10 months after submission (potentially H1 2027)
- Next catalyst
- None dated
What to watchThe BLA submission in Q3 2026 is the key near-term catalyst. The FDA has already aligned on the submission package, but final acceptance and review timelines remain to be seen. Watch for the official BLA filing announcement, PDUFA date assignment, and any FDA Advisory Committee meeting. The $225M June 2026 offering funds commercialization readiness but added ~8% dilution. Analysts are bullish (16 buy vs 5 hold, mean PT ~$64.59, ~47% upside from ~$44).
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Sep 2 $46.23entry
- T+1 · 3mo ago −2.96%α −4.01% · $44.86
- T+5 · 2mo ago −3.81%α −2.85% · $44.47
- T+20 · due 7w ago Pending
- T+52 · todayOpen
- T+60 · in 10d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
uniQure announced submission of a Biologics License Application (BLA) to the FDA seeking accelerated approval of its gene therapy ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, along with a parallel Marketing Authorisation Application (MAA) to the UK MHRA. The submissions are supported by three-year Phase I/II data showing slowed disease progression, and the company has requested priority review, which could shorten the FDA review cycle to six months. This is a major regulatory milestone for a first-in-class therapy addressing a large unmet need, though approval is not guaranteed and the stock has historically underperformed on high-impact events.
Key Facts
- BLA submitted to FDA for accelerated approval of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease
- MAA submitted to UK MHRA for the same therapy
- Priority review requested for the BLA; if granted, FDA review cycle would be six months after the 60-day filing review period
- Submissions supported by three-year data from Phase I/II study showing slowing of disease progression vs. propensity score-matched external control
- Company plans to present four-year data analysis from ongoing Phase I/II studies before end of current third quarter
- Ifezuntirgene inilparvovec holds FDA Breakthrough Therapy and RMAT designations, as well as Fast Track designation
Financial Impact
No financial figures disclosed; potential multi-billion-dollar market opportunity if approved for ~75,000 patients in U.S., EU, and UK with no currently approved disease-modifying therapies
Risk Factors
- FDA may not accept the BLA for filing or may deny priority review
- Phase I/II data may be deemed insufficient for accelerated approval; confirmatory study may be required
- Regulatory decisions in the UK (MHRA) are independent and may differ from FDA
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-104463 |
| Document: qure-20260902xex99d1.htm | 0001104659-26-104463 |
| Document: 0001104659-26-104463-index-headers.html | 0001104659-26-104463 |
| Document: 0001104659-26-104463-index.html | 0001104659-26-104463 |
| Document: 0001104659-26-104463.txt | 0001104659-26-104463 |
Track record
38 reports on QURE
6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Viewing Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers